ASP7373

UMN Pharma Inc. · Phase 2 active Biologic

At a glance

Generic name	ASP7373
Sponsor	UMN Pharma Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASP7373 CI brief — competitive landscape report
ASP7373 updates RSS · CI watch RSS
UMN Pharma Inc. portfolio CI